NanoViricides Says The Healthy Subjects Part Of The Phase 1a/1b Clinical Trial Of NV-CoV-2 Was Completed Successfully And No Adverse Events Were Reported In Any Of The Ascending Dose Cohorts
NanoViricides Says The Healthy Subjects Part Of The Phase 1a/1b Clinical Trial Of NV-CoV-2 Was Completed Successfully And No Adverse Events Were Reported In Any Of The Ascending Dose Cohorts
nanoviricides表示，NV-CoV-2的1a/1b期臨床試驗的健康受試者部分已成功完成，在任何劑量上升的隊列中均未報告任何不良事件
NanoViricides Says The Healthy Subjects Part Of The Phase 1a/1b Clinical Trial Of NV-CoV-2 Was Completed Successfully And No Adverse Events Were Reported In Any Of The Ascending Dose Cohorts
nanoviricides表示，NV-CoV-2的1a/1b期臨床試驗的健康受試者部分已成功完成，在任何劑量上升的隊列中均未報告任何不良事件
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。